Polycystic Ovary Syndrome
Conditions
Brief summary
Observe validity of Recombinant Human Growth Hormone Injection assisted in IVF-ET (in vitro fertilization and embryo transfer) treatment of PCOS (polycystic ovary syndrome) patients.
Interventions
DRUGConventional controlled ovarian stimulation proctol
Conventional controlled ovarian stimulation proctol without rhGH.
Sponsors
Peking University Third Hospital
Changchun GeneScience Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Age between 25 and 35 years old, married female and infertile. * BMI≥25kg/m2. * Diagnosed as PCOS. * No obvious chronic organic diseases, such as liver, kidney, heart, lung, thyroid, adrenal disease. * Subjects do not take part in other clinical trial study within 3 months. * The subjects sign the informed consent form.
Exclusion criteria
* BMI\<25kg/m2. * Hyperprolactinemia and congenital adrenal cortical hyperplasia. * Diabetes, thyroid function hyperthyroidism, thyroid dysfunction, cushing's syndrome. * Pelvic and peritoneal tumor and tumor secreting hyperandrogenism. * Severe acute and chronic liver and kidney disease, such as liver cirrhosis, acute and chronic renal failure, hepatitis B virus activity. * Liver and kidney dysfunction, AST/ALT is 2.5 times higher than the normal limit, the serum of creatinine is 2 times higher than the normal level. * Diseases affecting outcome of IVF pregnancy, eg, hydrosalpinx, hysteromyoma\>4 cm, adenomyosis, endometriosis, endometrial cyst of ovary, unilateral ovary, tuberculosis of reproductive system. * Allergic to E. coli. expression product and its excipients. * Being involved in other drug clinical researchers. * The researchers consider who is not suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate | One year |
| Number of fertilized oocytes | One year |
Secondary
| Measure | Time frame |
|---|---|
| Number of retrieved oocytes | One year |
| Number of high quality embryos | One year |
| Number of transferred embryos | One year |
Countries
China
Contacts
Primary ContactShuo Huang
Outcome results
None listed